

# Spillover Effects in Cluster Randomized Trials with Noncompliance

Hyunseung Kang<sup>1</sup> and Luke Keele<sup>2</sup>

April 12, 2021

---

<sup>1</sup>University of Wisconsin-Madison

<sup>2</sup>University of Pennsylvania

# Outline

- Background: Cluster Randomized Trials (CRTs) with Noncompliance
  - ▶ Motivation: School-wide deworming treatment in Kenya with noncompliance.

# Outline

- Background: Cluster Randomized Trials (CRTs) with Noncompliance
  - ▶ Motivation: School-wide deworming treatment in Kenya with noncompliance.
  - ▶ Problem: Spillover effects may also be present.

# Outline


- Background: Cluster Randomized Trials (CRTs) with Noncompliance
  - ▶ Motivation: School-wide deworming treatment in Kenya with noncompliance.
  - ▶ Problem: Spillover effects may also be present.
  - ▶ Goal: Investigate what happens when considering spillover effects in CRTs with noncompliance.

## Cluster Randomized Trials (CRTs)

- Sometimes, in CRTs, units do not actually take the offered treatment (or control): **noncompliance**

# Cluster Randomized Trials (CRTs)

- Sometimes, in CRTs, units do not actually take the offered treatment (or control): **noncompliance**



## Noncompliance in CRTs

We can use the instrumental variables (IV) methods to estimate the Complier Average Causal Effect (**CACE/LATE**) in a CRT:

## Noncompliance in CRTs

We can use the instrumental variables (IV) methods to estimate the Complier Average Causal Effect (**CACE/LATE**) in a CRT:

1. Estimate the **intent-to-treat (ITT) effect** by diff-in-“means:”  $\widehat{ITT}$



## Noncompliance in CRTs

We can use the instrumental variables (IV) methods to estimate the Complier Average Causal Effect (**CACE/LATE**) in a CRT:

1. Estimate the **intent-to-treat (ITT) effect** by diff-in-“means:”  $\widehat{ITT}$
2. Estimate the **number of compliers** by diff-in-means:  $\widehat{N}^{CO}$

## Noncompliance in CRTs


We can use the instrumental variables (IV) methods to estimate the Complier Average Causal Effect (**CACE/LATE**) in a CRT:

1. Estimate the **intent-to-treat (ITT) effect** by diff-in-“means:”  $\widehat{ITT}$
2. Estimate the **number of compliers** by diff-in-means:  $\widehat{N}^{CO}$
3. Take the ratio:  $\widehat{CACE} = \frac{\widehat{ITT}}{\widehat{N}^{CO}}$ , “IV/Wald estimator” or “TSLS”

Example: Deworming Treatment in Busia, Kenya  
[Miguel and Kremer, 2004]

# Example: Deworming Treatment in Busia, Kenya [Miguel and Kremer, 2004]


- **Intestinal helminths** are parasitic worms in humans that cause disease.



*Ascaris lumbricoides* Life Cycle, Nematode (Roundworm)


# Example: Deworming Treatment in Busia, Kenya [Miguel and Kremer, 2004]

- **Intestinal helminths** are parasitic worms in humans that cause disease.
- Helminths spread through outdoor exposure (e.g. outdoor defecation, infected water).



*Ascaris lumbricoides* Life Cycle, Nematode (Roundworm)

# Example: Deworming Treatment in Busia, Kenya [Miguel and Kremer, 2004]



*Ascaris lumbricoides* Life Cycle, Nematode (Roundworm)

- **Intestinal helminths** are parasitic worms in humans that cause disease.
- Helminths spread through outdoor exposure (e.g. outdoor defecation, infected water).
- Primary School Deworming Project (**PSDP**) was a public health intervention to reduce infection of intestinal helminths among schoolchildren.

## Example: Deworming Treatment

- PSDP studied the effect of deworming treatment with schools as clusters.

## Example: Deworming Treatment

- PSDP studied the effect of deworming treatment with schools as clusters.
  1. 25 (out of 50) schools randomized to new treatment; rest got control



## Example: Deworming Treatment


- PSDP studied the effect of deworming treatment with schools as clusters.
  1. 25 (out of 50) schools randomized to new treatment; rest got control
  2. Treated Schools: many students took treatment (82% complied)

## Example: Deworming Treatment

- PSDP studied the effect of deworming treatment with schools as clusters.
  1. 25 (out of 50) schools randomized to new treatment; rest got control
  2. Treated Schools: many students took treatment (82% complied)
  3. Control Schools: stuck with control; **one-sided noncompliance**


## Example: Deworming Treatment

- PSDP studied the effect of deworming treatment with schools as clusters.
  - 25 (out of 50) schools randomized to new treatment; rest got control
  - Treated Schools: many students took treatment (82% complied)
  - Control Schools: stuck with control; **one-sided noncompliance**



## Example: Deworming Treatment


- PSDP studied the effect of deworming treatment with schools as clusters.
  - 25 (out of 50) schools randomized to new treatment; rest got control
  - Treated Schools: many students took treatment (82% complied)
  - Control Schools: stuck with control; **one-sided noncompliance**



- Record presence of helminth infection (i.e. binary outcome)

## Example: Deworming Treatment

- PSDP studied the effect of deworming treatment with schools as clusters.
  - 25 (out of 50) schools randomized to new treatment; rest got control
  - Treated Schools: many students took treatment (82% complied)
  - Control Schools: stuck with control; **one-sided noncompliance**



- Record presence of helminth infection (i.e. binary outcome)
- $\widehat{CATE} = -0.41$ ; taking meds reduced infection (on avg.) by **41%** among compliers)

# Treatment Spillovers

# Treatment Spillovers

There are **two** main ways for the deworming treatment to reduce infection:

# Treatment Spillovers

There are **two** main ways for the deworming treatment to reduce infection:

1. Treating those who are infected (**direct effect**)
  - ▶ Joe takes medication  $\Rightarrow$  kills worms & Joe feels healthy



# Treatment Spillovers

There are **two** main ways for the deworming treatment to reduce infection:

1. Treating those who are infected (**direct effect**)
  - ▶ Joe takes medication  $\Rightarrow$  kills worms & Joe feels healthy
2. Reducing the number of helminths in the environment, making it less likely for peers to contract them (**spillover effect**)
  - ▶ Jane takes medication  $\Rightarrow$  kills worms & Jane feels healthy  $\Rightarrow$  worms no longer spread to Jane's friends.

# Treatment Spillovers

There are **two** main ways for the deworming treatment to reduce infection:

1. Treating those who are infected (**direct effect**)
  - ▶ Joe takes medication  $\Rightarrow$  kills worms & Joe feels healthy
2. Reducing the number of helminths in the environment, making it less likely for peers to contract them (**spillover effect**)
  - ▶ Jane takes medication  $\Rightarrow$  kills worms & Jane feels healthy  $\Rightarrow$  worms no longer spread to Jane's friends.

Thus, there could be a direct and indirect effect of treatment.

# Treatment Spillovers

# Treatment Spillovers

- The CRT design is often used to limit treatment spillovers.

# Treatment Spillovers

- The CRT design is often used to limit treatment spillovers.
- That is, we assume no spillovers across clusters.

# Treatment Spillovers

- The CRT design is often used to limit treatment spillovers.
- That is, we assume no spillovers across clusters.
- Noncompliance opens the door for spillovers within clusters, since not all units in each cluster are exposed.

## Key Questions In This Paper...

## Key Questions In This Paper...

- Q1: Does the standard IV analysis of CRTs with noncompliance **actually** estimate the complier average treatment effect (CATE) when spillover effects are present?



## Key Questions In This Paper...

- Q1: Does the standard IV analysis of CRTs with noncompliance **actually** estimate the complier average treatment effect (CATE) when spillover effects are present?
- Q2: Can **any** analysis of CRTs estimate relevant network effects (direct effect, spillover effect, etc.)?

## Key Questions In This Paper...

- Q1: Does the standard IV analysis of CRTs with noncompliance **actually** estimate the complier average treatment effect (CATE) when spillover effects are present?
- Q2: Can **any** analysis of CRTs estimate relevant network effects (direct effect, spillover effect, etc.)?
- Q3: What can we **learn** from CRT data, specifically to understand network causal effects?

# Noncompliance in CRTs

## Noncompliance in CRTs

Angrist, Imbens, Rubin (1996): IV framework classifies units into one of four types based on response to treatment/control offering

## Noncompliance in CRTs

Angrist, Imbens, Rubin (1996): IV framework classifies units into one of four types based on response to treatment/control offering

- **Always-Takers (AT)**: Always take treatment, even if not offered.

## Noncompliance in CRTs

Angrist, Imbens, Rubin (1996): IV framework classifies units into one of four types based on response to treatment/control offering

- **Always-Takers (AT)**: Always take treatment, even if not offered.
- **Compliers (CO)**: Take treatment only when offered.

## Noncompliance in CRTs

Angrist, Imbens, Rubin (1996): IV framework classifies units into one of four types based on response to treatment/control offering

- **Always-Takers (AT)**: Always take treatment, even if not offered.
- **Compliers (CO)**: Take treatment only when offered.
- **Never-Takers (NT)**: Never take treatment, even if offered.

## Noncompliance in CRTs

Angrist, Imbens, Rubin (1996): IV framework classifies units into one of four types based on response to treatment/control offering

- **Always-Takers (AT)**: Always take treatment, even if not offered.
- **Compliers (CO)**: Take treatment only when offered.
- **Never-Takers (NT)**: Never take treatment, even if offered.
- **Defiers (DF)**: Systematically defy treatment offer.



## Q1: Three Causal Estimands

## Q1: Three Causal Estimands

- **Total Effect Among Compliers (CO):**
  - ▶ You only take meds if you're told to do so.
  - ▶ Are you better off if you and  $k_1$  peers took deworming meds compared to if you didn't take meds and  $k_0 < k_1$  peers took meds?

## Q1: Three Causal Estimands

- **Total Effect Among Compliers (CO):**
  - ▶ You only take meds if you're told to do so.
  - ▶ Are you better off if you and  $k_1$  peers took deworming meds compared to if you didn't take meds and  $k_0 < k_1$  peers took meds?
- **Spillover Effect Among Always-Takers (AT):**
  - ▶ You always take meds.
  - ▶ If  $k_1 - k_0$  more friends take deworming meds, are you less likely to be infected?

## Q1: Three Causal Estimands

- **Total Effect Among Compliers (CO):**
  - ▶ You only take meds if you're told to do so.
  - ▶ Are you better off if you and  $k_1$  peers took deworming meds compared to if you didn't take meds and  $k_0 < k_1$  peers took meds?
- **Spillover Effect Among Always-Takers (AT):**
  - ▶ You always take meds.
  - ▶ If  $k_1 - k_0$  more friends take deworming meds, are you less likely to be infected?
- **Spillover Effect Among Never-Takers (NT):**
  - ▶ You never take meds.
  - ▶ If  $k_1 - k_0$  more friends take deworming meds, are you less likely to be infected?

Q1: Standard IV Analysis Does Not Identify CACE

## Q1: Standard IV Analysis Does Not Identify CACE

1. Main Point: Standard IV estimates (e.g. 41% reduction of infection) identifies a **mixture** of effects under interference, not CACE!

# Q1: Standard IV Analysis Does Not Identify CACE

1. Main Point: Standard IV estimates (e.g. 41% reduction of infection) identifies a **mixture** of effects under interference, not CACE!
2. IV strength (i.e. compliance to treatment) and subgroup effects
  - ▶ If IV is strong (i.e. many COs), IV estimator  $\approx \left[ \begin{array}{c} \text{Total Effect} \\ \text{Among COs} \end{array} \right]$
  - ▶ If IV is weak (i.e. few COs), IV estimator  $\approx \left[ \begin{array}{c} \text{Spillover Effects} \\ \text{Among NTs and ATs} \end{array} \right]$

Q2: Can **any** analysis of CRTs estimate relevant network effects (direct effects, spillover effects, etc.)



Q2: Can **any** analysis of CRTs estimate relevant network effects (direct effects, spillover effects, etc.)

**No.**

Q2: Can **any** analysis of CRTs estimate relevant network effects (direct effects, spillover effects, etc.)

**No.**

Theorem

*Consider the “numerators” of the three causal quantities of interest: (1) **total effect among CO**, (2) **spillover effect among ATs**, and (3) **spillover effect among NTs**. There does not exist unbiased estimators for these quantities.*

Q2: Can **any** analysis of CRTs estimate relevant network effects (direct effects, spillover effects, etc.)

**No.**

Theorem

*Consider the “numerators” of the three causal quantities of interest: (1) **total effect among CO**, (2) **spillover effect among ATs**, and (3) **spillover effect among NTs**. There does not exist unbiased estimators for these quantities.*

1. Main Point: CRTs, as a design, are **generally inadequate** to study spillover effects when noncompliance is present
  - ▶ Fix 1: Make more assumptions
  - ▶ Fix 2: Create “robust” designs (e.g. peer encouragement designs?)

### Q3: What can we **learn** from CRT data?

- (A6) **Treatment is not harmful.** You (or your friend) taking the treatment cannot hurt you.

### Q3: What can we **learn** from CRT data?

- (A6) **Treatment is not harmful.** You (or your friend) taking the treatment cannot hurt you.
- ▶ Total effect and spillover effect of each individual are non-negative.
  - ▶ Plausible when treatment provides benefit (e.g. meds, vaccines, etc.)

### Q3: What can we **learn** from CRT data?

- (A6) **Treatment is not harmful.** You (or your friend) taking the treatment cannot hurt you.
- ▶ Total effect and spillover effect of each individual are non-negative.
  - ▶ Plausible when treatment provides benefit (e.g. meds, vaccines, etc.)
- Result 1: Bounds on network effects are possible.

### Q3: What can we **learn** from CRT data?

- (A6) **Treatment is not harmful.** You (or your friend) taking the treatment cannot hurt you.
- ▶ Total effect and spillover effect of each individual are non-negative.
  - ▶ Plausible when treatment provides benefit (e.g. meds, vaccines, etc.)
- 
- Result 1: Bounds on network effects are possible.
  
  - Result 2: Consistent estimation of bounds are possible, using standard IV methods.

## Q3: What can we **learn** from CRT data?

- (A6) **Treatment is not harmful.** You (or your friend) taking the treatment cannot hurt you.
- ▶ Total effect and spillover effect of each individual are non-negative.
  - ▶ Plausible when treatment provides benefit (e.g. meds, vaccines, etc.)
- Result 1: Bounds on network effects are possible.
  - Result 2: Consistent estimation of bounds are possible, using standard IV methods.
  - Result 3: Point-wise, permutation-based inference for bounds are possible.



# Consistent Estimation of Bounds

## Consistent Estimation of Bounds

- We need to estimate  $N^{\text{NT}}$ ,  $N^{\text{CO}}$ , and  $\tau = \text{“CACE”}$

## Consistent Estimation of Bounds

- We need to estimate  $N^{\text{NT}}$ ,  $N^{\text{CO}}$ , and  $\tau = \text{“CACE”}$
- Estimation of these quantities require only standard IV methods

$\hat{\tau}$  = standard IV/Wald/TSLS estimator

$\hat{N}^{\text{CO}}$  = denominator of  $\hat{\tau}$  estimator

$\hat{N}^{\text{NT}} = N - \hat{N}^{\text{CO}}$

## Consistent Estimation of Bounds

- We need to estimate  $N^{\text{NT}}$ ,  $N^{\text{CO}}$ , and  $\tau = \text{“CACE”}$
- Estimation of these quantities require only standard IV methods

$\hat{\tau} = \text{standard IV/Wald/TSLS estimator}$

$\hat{N}^{\text{CO}} = \text{denominator of } \hat{\tau} \text{ estimator}$

$\hat{N}^{\text{NT}} = N - \hat{N}^{\text{CO}}$

- You plug in these estimates to min/max bounds.

## Consistent Estimation of Bounds

- We need to estimate  $N^{\text{NT}}$ ,  $N^{\text{CO}}$ , and  $\tau = \text{“CACE”}$
- Estimation of these quantities require only standard IV methods

$\hat{\tau} = \text{standard IV/Wald/TSLS estimator}$

$\hat{N}^{\text{CO}} = \text{denominator of } \hat{\tau} \text{ estimator}$

$\hat{N}^{\text{NT}} = N - \hat{N}^{\text{CO}}$

- You plug in these estimates to min/max bounds.
- They are consistent if (i) cluster sizes are bounded, (ii) IV isn't weak, (iii) (essentially)  $\text{TE}^{\text{CO}}$  and  $\text{PE}^{\text{NT}}$  are stable in asymptopia.

# Revisiting the Deworming Treatment in Busia, Kenya

## Revisiting the Deworming Treatment in Busia, Kenya

Setup:  $J = 50$  schools (i.e. clusters), 4 to 80 students per cluster.

1. Schools randomly assigned deworming treatments (oral medications) or control.
2. Students choose to take treatment ( $D_{ji} = 1$ ) or not ( $D_{ji} = 0$ ).
3. Outcome is presence of worm infection ( $Y_{ji} = 1$  yes,  $Y_{ji} = 0$  no)

# Revisiting the Deworming Treatment in Busia, Kenya

Setup:  $J = 50$  schools (i.e. clusters), 4 to 80 students per cluster.

1. Schools randomly assigned deworming treatments (oral medications) or control.
2. Students choose to take treatment ( $D_{ji} = 1$ ) or not ( $D_{ji} = 0$ ).
3. Outcome is presence of worm infection ( $Y_{ji} = 1$  yes,  $Y_{ji} = 0$  no)

Note 1: One-sided noncompliance; students in control clusters can't take meds even if they wanted to.

Note 2: Both noncompliance and interference plausible.



# Revisiting the Deworming Treatment in Busia, Kenya

## Revisiting the Deworming Treatment in Busia, Kenya

	Point Est.	Uncertainty
Compliance rate (i.e. % COs)	82%	95% CI (71%, 93%)
Standard IV method (IV/Wald estimator)	$\hat{\tau} = -0.41$	95% CI (-0.29, -0.53)
Bound on total effect among COs	reduced infection from 12% to 79%	95% CI* (0%, 100%)
Bound on spillover effect among NTs	reduced infection from 0% to 100%	95% CI* (0%, 100%)

# Summary

- Goal: Investigate what happens when interference is present in CRTs with noncompliance

## Summary

- Goal: Investigate what happens when interference is present in CRTs with noncompliance
- Q1: Does the standard IV analysis of CRTs with noncompliance **actually** estimate the complier average treatment effect (CATE) when spillover effects are present?  
A: **No**. It estimates a **mixture** of effects from different subgroups.

## Summary

- Goal: Investigate what happens when interference is present in CRTs with noncompliance
- Q1: Does the standard IV analysis of CRTs with noncompliance **actually** estimate the complier average treatment effect (CATE) when spillover effects are present?  
A: **No**. It estimates a **mixture** of effects from different subgroups.
- Q2: Can **any** analysis of CRTs estimate other (network) causal effects (spillover effects, total effects, etc.)  
A: **No**. You can't **unbiasedly estimate** network effects from CRT data with noncompliance.

# Summary

# Summary

- Q3: What can we **learn** from CRT data, specifically to understand network causal effects?
  - A1: **Bounds** on total and spillover effects under treatment monotonicity with standard IV analysis
  - A2: Informative bounds  $\propto$  **IV strength** + **standard IV analysis**.

## Bibliography

- E. Miguel and M. Kremer. Worms: identifying impacts on education and health in the presence of treatment externalities. *Econometrica*, 72(1):159–217, 2004.